Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
F 43.29 6.99% 2.83
RLAY closed up 6.99 percent on Wednesday, February 24, 2021, on 84 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical RLAY trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 6.99%
Oversold Stochastic Weakness 6.99%
Bullish Engulfing Bullish -1.66%
Pocket Pivot Bullish Swing Setup -1.66%
NR7 Range Contraction -1.66%
Inside Day Range Contraction -1.66%
Wide Bands Range Expansion -1.66%
Oversold Stochastic Weakness -1.66%
Older End-of-Day Signals for RLAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 10 DMA about 6 hours ago
Rose Above Previous Day's High about 7 hours ago
10 DMA Resistance about 7 hours ago
Up 10% about 7 hours ago
Up 1 ATR about 7 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 64.0
52 Week Low 32.56
Average Volume 692,670
200-Day Moving Average 0.00
50-Day Moving Average 46.93
20-Day Moving Average 47.57
10-Day Moving Average 44.27
Average True Range 3.82
ADX 14.98
+DI 16.54
-DI 19.84
Chandelier Exit (Long, 3 ATRs ) 51.50
Chandelier Exit (Short, 3 ATRs ) 51.65
Upper Bollinger Band 55.15
Lower Bollinger Band 39.99
Percent B (%b) 0.22
BandWidth 31.87
MACD Line -1.72
MACD Signal Line -0.91
MACD Histogram -0.8111
Fundamentals Value
Market Cap 3.9 Billion
Num Shares 90 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -43.73
Price-to-Sales 0.00
Price-to-Book 6.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.50
Resistance 3 (R3) 50.38 47.86 49.30
Resistance 2 (R2) 47.86 46.02 47.92 48.90
Resistance 1 (R1) 45.57 44.89 46.72 45.69 48.50
Pivot Point 43.05 43.05 43.62 43.11 43.05
Support 1 (S1) 40.77 41.22 41.91 40.89 38.08
Support 2 (S2) 38.25 40.08 38.31 37.68
Support 3 (S3) 35.96 38.25 37.28
Support 4 (S4) 36.08